vs
Ingevity Corp（NGVT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Ingevity Corp的1.1倍（$207.3M vs $185.4M），Ingevity Corp净利率更高（-45.6% vs -62.0%，领先16.4%），Ingevity Corp同比增速更快（36.7% vs 25.9%），Ingevity Corp自由现金流更多（$73.5M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -26.2%）
Ingevity Corp是一家全球特种化学品与先进材料生产商，主营高性能碳材料、路面养护解决方案及特种化工产品，服务汽车排放控制、工业净化、道路基建、农业投入品等核心市场，业务覆盖北美、欧洲及亚太地区。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NGVT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.4M | $207.3M |
| 净利润 | $-84.6M | $-128.6M |
| 毛利率 | 41.2% | — |
| 营业利润率 | -47.7% | -54.7% |
| 净利率 | -45.6% | -62.0% |
| 营收同比 | 36.7% | 25.9% |
| 净利润同比 | -609.6% | 3.5% |
| 每股收益（稀释后） | $-2.33 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $185.4M | $207.3M | ||
| Q3 25 | $333.1M | $159.9M | ||
| Q2 25 | $365.1M | $166.5M | ||
| Q1 25 | $284.0M | $139.3M | ||
| Q4 24 | $135.6M | $164.6M | ||
| Q3 24 | $333.8M | $139.5M | ||
| Q2 24 | $390.6M | $147.0M | ||
| Q1 24 | $340.1M | $108.8M |
| Q4 25 | $-84.6M | $-128.6M | ||
| Q3 25 | $43.5M | $-180.4M | ||
| Q2 25 | $-146.5M | $-115.0M | ||
| Q1 25 | $20.5M | $-151.1M | ||
| Q4 24 | $16.6M | $-133.2M | ||
| Q3 24 | $-107.2M | $-133.5M | ||
| Q2 24 | $-283.7M | $-131.6M | ||
| Q1 24 | $-56.0M | $-170.7M |
| Q4 25 | 41.2% | — | ||
| Q3 25 | 40.2% | — | ||
| Q2 25 | 37.8% | — | ||
| Q1 25 | 39.9% | — | ||
| Q4 24 | 81.3% | — | ||
| Q3 24 | 39.4% | — | ||
| Q2 24 | 31.5% | — | ||
| Q1 24 | 29.3% | — |
| Q4 25 | -47.7% | -54.7% | ||
| Q3 25 | 18.7% | -106.9% | ||
| Q2 25 | -39.1% | -64.8% | ||
| Q1 25 | 9.4% | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | 33.0% | -94.6% | ||
| Q2 24 | 25.9% | -79.1% | ||
| Q1 24 | 22.6% | -151.9% |
| Q4 25 | -45.6% | -62.0% | ||
| Q3 25 | 13.1% | -112.8% | ||
| Q2 25 | -40.1% | -69.0% | ||
| Q1 25 | 7.2% | -108.5% | ||
| Q4 24 | 12.2% | -80.9% | ||
| Q3 24 | -32.1% | -95.7% | ||
| Q2 24 | -72.6% | -89.5% | ||
| Q1 24 | -16.5% | -156.8% |
| Q4 25 | $-2.33 | $-1.28 | ||
| Q3 25 | $1.18 | $-1.81 | ||
| Q2 25 | $-4.02 | $-1.17 | ||
| Q1 25 | $0.56 | $-1.57 | ||
| Q4 24 | $0.44 | $-1.34 | ||
| Q3 24 | $-2.94 | $-1.40 | ||
| Q2 24 | $-7.81 | $-1.52 | ||
| Q1 24 | $-1.54 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.1M | $421.0M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $29.7M | $-80.0M |
| 总资产 | $1.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 39.10× | — |
8季度趋势，按日历期对齐
| Q4 25 | $78.1M | $421.0M | ||
| Q3 25 | $83.4M | $202.5M | ||
| Q2 25 | $76.9M | $176.3M | ||
| Q1 25 | $71.5M | $127.1M | ||
| Q4 24 | $68.0M | $174.0M | ||
| Q3 24 | $135.5M | $150.6M | ||
| Q2 24 | $107.4M | $480.7M | ||
| Q1 24 | $88.5M | $112.3M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $29.7M | $-80.0M | ||
| Q3 25 | $138.1M | $9.2M | ||
| Q2 25 | $120.7M | $151.3M | ||
| Q1 25 | $234.6M | $144.2M | ||
| Q4 24 | $195.2M | $255.0M | ||
| Q3 24 | $214.5M | $346.8M | ||
| Q2 24 | $284.8M | $432.4M | ||
| Q1 24 | $568.2M | $140.3M |
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | $1.8B | $1.2B | ||
| Q2 25 | $1.9B | $1.3B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.0B | $1.5B | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B | ||
| Q1 24 | $2.6B | $1.3B |
| Q4 25 | 39.10× | — | ||
| Q3 25 | 8.39× | — | ||
| Q2 25 | 10.24× | — | ||
| Q1 25 | 5.68× | — | ||
| Q4 24 | 6.86× | — | ||
| Q3 24 | 6.52× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 2.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $73.5M | $-100.8M |
| 自由现金流率自由现金流/营收 | 39.6% | -48.6% |
| 资本支出强度资本支出/营收 | 12.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $273.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $97.1M | $-99.8M | ||
| Q3 25 | $129.7M | $-91.4M | ||
| Q2 25 | $79.0M | $-108.3M | ||
| Q1 25 | $25.4M | $-166.5M | ||
| Q4 24 | $64.5M | $-79.3M | ||
| Q3 24 | $46.5M | $-67.0M | ||
| Q2 24 | $29.7M | $-77.0M | ||
| Q1 24 | $-12.1M | $-190.7M |
| Q4 25 | $73.5M | $-100.8M | ||
| Q3 25 | $117.8M | $-92.7M | ||
| Q2 25 | $66.8M | $-110.7M | ||
| Q1 25 | $15.4M | $-167.8M | ||
| Q4 24 | $39.6M | $-79.5M | ||
| Q3 24 | $28.5M | $-68.6M | ||
| Q2 24 | $11.6M | $-79.0M | ||
| Q1 24 | $-28.7M | $-193.9M |
| Q4 25 | 39.6% | -48.6% | ||
| Q3 25 | 35.4% | -58.0% | ||
| Q2 25 | 18.3% | -66.5% | ||
| Q1 25 | 5.4% | -120.5% | ||
| Q4 24 | 29.2% | -48.3% | ||
| Q3 24 | 8.5% | -49.2% | ||
| Q2 24 | 3.0% | -53.7% | ||
| Q1 24 | -8.4% | -178.2% |
| Q4 25 | 12.7% | 0.5% | ||
| Q3 25 | 3.6% | 0.8% | ||
| Q2 25 | 3.3% | 1.5% | ||
| Q1 25 | 3.5% | 1.0% | ||
| Q4 24 | 18.4% | 0.1% | ||
| Q3 24 | 5.4% | 1.2% | ||
| Q2 24 | 4.6% | 1.4% | ||
| Q1 24 | 4.9% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.98× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
